Health
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Publication: STAT
Author: Ed Silverman
Source published: 28/09/2026, 13:06:52 UTC
Briefing created: 28/09/2026, 13:22:36 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 13:21:24 UTC.
Briefings
GLP-1 drugs, previously marketed as obesity treatments, are shifting toward general wellness, causing setbacks for pharmaceutical companies like Merck and Daiichi Sankyo. Novo Nordisk has expanded its direct-to-consumer strategy, while Merck and Daiichi withdrew U.S. applications for experimental lung cancer therapies after mid-stage clinical studies failed to meet FDA approval criteria. This represents a second pullback in their cancer drug alliance, following a similar failure with a late-stage lung cancer candidate last year.
Key points
- GLP-1 drugs are increasingly marketed as general wellness products rather than obesity treatments, leading to reduced insurance coverage and direct-to-consumer sales strategies.
- Merck and Daiichi Sankyo withdrew U.S. applications for experimental lung cancer therapies after mid-stage clinical studies failed to satisfy FDA requirements for early green light approval.
Context and limitations
Data reflects a 2026 working week snapshot; coverage is limited to the provided text, which does not include specific patient outcomes, exact financial figures, or future regulatory forecasts.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 13:22:36 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeicobshm6pq7bqne4dfht5tukpq3vdlr77pkuk6zc4wux7ek4yslma